{"id":370,"date":"2021-04-03T12:00:23","date_gmt":"2021-04-03T10:00:23","guid":{"rendered":"http:\/\/lr-cannabis.www.bioevents.net\/?page_id=370"},"modified":"2022-08-09T11:01:56","modified_gmt":"2022-08-09T09:01:56","slug":"dear-colleague","status":"publish","type":"page","link":"https:\/\/euroleuk2022.com\/dear-colleague\/","title":{"rendered":"Dear Colleague"},"content":{"rendered":"

It is with great pleasure that we invite you to join us in person at The 3rd European Congress on Controversies in Leukemias<\/strong>\u00a0(Euroleuk2022)<\/strong>\u00a0which will take place 2-3 November 2022 in Copenhagen, Denmark.<\/strong><\/span><\/p>\n

Following on from the highly successful Euroleuk2020 and Euroleuk2021, Euroleuk2022 will continue to provide clinicians and biologists with state-of-the-art recommendations regarding patient care and insights into controversies and new therapeutic perspectives in the field and will be of interest to:<\/span>
\n\u2022\u00a0 Senior or junior clinicians (MD, PhD, MD-PhD)<\/span>
\n\u2022\u00a0 Biologists (BS)<\/span>
\n\u2022\u00a0 Clinical residents in-training<\/span>
\n\u2022\u00a0 R&D personnel<\/span>
\n\u2022\u00a0 Pharmaceutical and industry professionals.<\/span><\/p>\n

The most relevant and latest controversies on the following topics will be discussed:<\/span>
\n\u2022\u00a0 Biology of ALL, AML CML, CLL<\/span>
\n\u2022\u00a0 Leukemia stem cells (LSCs)<\/span>
\n\u2022\u00a0 Routing diagnosis gene expression and mutational profiling<\/span>
\n\u2022\u00a0 Allogeneic hematopoietic stem cell transplantation<\/span>
\n\u2022\u00a0 Front-line treatment of ALL, AML, CML, CLL<\/span>
\n\u2022\u00a0 Treatment of resistant\/relapsed disease<\/span>
\n\u2022\u00a0 How novel agents are changing the treatment landscape of ALL, AML, CML, CLL<\/span>
\n\u2022\u00a0 Immunotherapy<\/span>
\n\u2022\u00a0 Minimal residual disease<\/span><\/p>\n

Join us and benefit from;<\/span><\/p>\n